397 related articles for article (PubMed ID: 26455457)
1. New insight into the therapeutic role of the serotonergic system in Parkinson's disease.
Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M
Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457
[TBL] [Abstract][Full Text] [Related]
2. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
Huot P; Fox SH; Newman-Tancredi A; Brotchie JM
J Pharmacol Exp Ther; 2011 Oct; 339(1):2-8. PubMed ID: 21784889
[TBL] [Abstract][Full Text] [Related]
3. Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.
Huot P; Sgambato-Faure V; Fox SH; McCreary AC
ACS Chem Neurosci; 2017 May; 8(5):973-986. PubMed ID: 28460160
[TBL] [Abstract][Full Text] [Related]
4. The serotonergic system in motor and non-motor manifestations of Parkinson's disease.
Huot P; Fox SH
Exp Brain Res; 2013 Oct; 230(4):463-76. PubMed ID: 23811734
[TBL] [Abstract][Full Text] [Related]
5. Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.
Shimizu S; Ohno Y
Aging Dis; 2013 Feb; 4(1):1-13. PubMed ID: 23423244
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions.
Ohno Y; Shimizu S; Tokudome K
Biol Pharm Bull; 2013; 36(9):1396-400. PubMed ID: 23995648
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
8. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
9. Serotonin and Parkinson's disease: On movement, mood, and madness.
Fox SH; Chuang R; Brotchie JM
Mov Disord; 2009 Jul; 24(9):1255-66. PubMed ID: 19412960
[TBL] [Abstract][Full Text] [Related]
10. New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders.
Ohno Y
Cent Nerv Syst Agents Med Chem; 2010 Jun; 10(2):148-57. PubMed ID: 20518729
[TBL] [Abstract][Full Text] [Related]
11. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
12. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.
Quik M; Bordia T; Zhang D; Perez XA
Int Rev Neurobiol; 2015; 124():247-71. PubMed ID: 26472532
[TBL] [Abstract][Full Text] [Related]
13. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
14. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Nicholson SL; Brotchie JM
Eur J Neurol; 2002 Nov; 9 Suppl 3():1-6. PubMed ID: 12464115
[TBL] [Abstract][Full Text] [Related]
15. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
16. What can we expect from the serotonergic side of L-DOPA?
De Deurwaerdère P; Navailles S
Rev Neurol (Paris); 2012 Dec; 168(12):927-38. PubMed ID: 22560009
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
18. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Ko WK; Li Q; Bezard E
Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
[TBL] [Abstract][Full Text] [Related]
19. Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions.
Shimizu S; Mizuguchi Y; Ohno Y
CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):861-9. PubMed ID: 23844689
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
